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Sir,
We thank Dr Floriani and co-workers for their interest in our work
and for their stimulating comments. It is important to highlight
that so far in metastatic colorectal cancer patients, treatment with
cetuximab or panitumumab is accomplished to block or to destroy
metastatic cells, whereas the evaluation of molecular markers able
to predict the efficacy of these therapies has been performed
mostly on primary tumours. Historically, the choice of researchers
to use primary tumours for molecular studies was made because
biopsies of the metastatic lesions were not available in the majority
of patients. As a consequence, it is reasonable to hypothesise that
primary tumours and related distant metastatic lesions may show
different molecular fingerprints that may affect the prediction of
response to targeted therapies.
We agree with Floriani and co-workers that K-Ras is the only
universally accepted determinant of resistance to EGFR-targeted
drugs. However, recent pre-clinical (Di Nicolantonio et al, 2008;
Jhawer et al, 2008) and clinical (Frattini et al, 2007; Di
Nicolantonio et al, 2008; Sartore-Bianchi et al, 2009) data show
that other members of the EGFR downstream pathways (e.g.,
BRAF, PTEN and PIK3CA) may have a predictive role in this
context. We found a rationale for our studies as no previous
works reported a simultaneous comparison of these markers in the
same cohort of patients. To evaluate the discrepancies between
primary tumour and paired distant metastatic lesions, we
applied Cohen’s kappa test, one of the most used and solid tests
for this type of work. Our results are in line with the few data
available in the literature on this topic and, although not
statistically significant, the results suggest that differences between
primary tumour and metastases may be clinically relevant for a
given patient. We are therefore pleased that Floriani and co-
workers after reading our work came to the same conclusions,
namely that prospective studies on this important topic are
extremely urgent.
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